GREENVILLE, S.C.--(BUSINESS WIRE)--Kiyatec, the leader in clinically correlated, published functional precision oncology evidence today announced the company is sponsoring and exhibiting at the virtual American Brain Tumor Association 2022 National Conference September 9-10, 2022. Details regarding this event can be found here: https://www.abta.org/national-conference-2022/
The ABTA National Conference is the only advocacy-led educational meeting designed specifically for patients, survivors and caregivers that brings together the entire brain tumor community. Held annually, thousands of attendees learn from the nation’s leading experts about the latest advances in brain tumor research, treatment and care.
Leveraging its innovative 3D cell culture technology platform for both clinical and pre-clinical use, Kiyatec recently introduced its first commercial assay in the US, 3D Predict™ Glioma. The Company is accelerating its commercial and business development services while securing payer pricing, coverage and reimbursement. The Kiyatec assay for ovarian cancer continues its evidence generation in ovarian cancer. Kiyatec is finalizing its facilities expansion in support of the Company’s five-year growth plan with increased laboratory capacity and accelerating its ex vivo 3D cell culture assay development in rare, breast and lung cancers.
About Kiyatec
Kiyatec is the first functional precision oncology company with published, clinically correlated evidence measuring the predictive therapeutic response of patient live cancer cells using its innovative 3D cell culture technology platform. The Company offers clinical tests for high-grade glioma and is developing tests for ovarian, breast, non-small cell lung and rare tumors in its CLIA-certified lab. The Company works with leading biopharmaceutical companies to unlock response dynamics for their investigational drug candidates across the majority of solid tumor types. For more information, visit www.kiyatec.com and connect with us on LinkedIn and Twitter.
